Atlas Trials

Regorafenib Alone or in Combined With Transcatheter Arterial ChEmoembolization in Treatment of Advanced Hepatocellular Carcinoma After First Line Targeted Therapy

Clinical trial NCT05811481 · UNKNOWN

Trial details

NCT number
NCT05811481
Sponsor
WenBo Guo
Status
UNKNOWN
Study type
OBSERVATIONAL
Hepatocellular CarcinomaTranscatheter Arterial ChEmoembolizationRegorafenib
Start date
2022-12-27
Primary completion
2024-12-27
Enrollment
192

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.